Research Progress on Structure and Anti-Gynecological Malignant Tumor of Shikonin
- PMID: 35873044
- PMCID: PMC9304652
- DOI: 10.3389/fchem.2022.935894
Research Progress on Structure and Anti-Gynecological Malignant Tumor of Shikonin
Abstract
Gynecological malignancy seriously threatens the physical and mental health of women. Shikonin is a naphthoquinone compound with a variety of biological activities. Studies have shown that shikonin can inhibit cell proliferation, promote cell apoptosis and induce cell necrosis. And in recent years, shikonin are also being increasingly used for the study of gynecological malignant diseases. Therefore, we reviewed the mechanism of action and structure optimization of shikonin in gynecological malignant tumors, in order to provide some reference for further research and development of related drug.
Keywords: anti-cancer; gynecological malignancy; review; shikonin; structural modification.
Copyright © 2022 Ke, Kong, Xu, Chen, Dong, Li, Zeng and Wang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures





Similar articles
-
Research progress on the structural and anti-colorectal malignant tumor properties of Shikonin.J Cancer Res Ther. 2024 Dec 1;20(7):1957-1963. doi: 10.4103/jcrt.jcrt_933_24. Epub 2025 Jan 10. J Cancer Res Ther. 2024. PMID: 39792404 Review.
-
TRAIL Enhances Shikonin Induced Apoptosis through ROS/JNK Signaling in Cholangiocarcinoma Cells.Cell Physiol Biochem. 2017;42(3):1073-1086. doi: 10.1159/000478758. Epub 2017 Jun 29. Cell Physiol Biochem. 2017. PMID: 28662515
-
Shikonin inhibits TNF-α-induced growth and invasion of rat aortic vascular smooth muscle cells.Can J Physiol Pharmacol. 2015 Aug;93(8):615-24. doi: 10.1139/cjpp-2014-0464. Epub 2015 Mar 18. Can J Physiol Pharmacol. 2015. PMID: 26042337
-
Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.Sci Rep. 2018 Feb 20;8(1):3317. doi: 10.1038/s41598-018-21570-z. Sci Rep. 2018. PMID: 29463831 Free PMC article.
-
Anti-cancer Research on Arnebiae radix-derived Naphthoquinone in Recent Five Years.Recent Pat Anticancer Drug Discov. 2022;17(3):218-230. doi: 10.2174/1574892816666211209164745. Recent Pat Anticancer Drug Discov. 2022. PMID: 34886780 Review.
Cited by
-
Upregulation of Succinate Dehydrogenase (SDHA) Contributes to Enhanced Bioenergetics of Ovarian Cancer Cells and Higher Sensitivity to Anti-Metabolic Agent Shikonin.Cancers (Basel). 2022 Oct 18;14(20):5097. doi: 10.3390/cancers14205097. Cancers (Basel). 2022. PMID: 36291881 Free PMC article.
-
Integration of active ingredients from traditional Chinese medicine with nano-delivery systems for tumor immunotherapy.J Nanobiotechnology. 2025 May 17;23(1):357. doi: 10.1186/s12951-025-03378-y. J Nanobiotechnology. 2025. PMID: 40382641 Free PMC article. Review.
-
Shikonin inhibits epithelial-mesenchymal transition in glioblastoma cells by upregulating p53 and promoting miR-361-5p level to suppress ZEB1 expression.BMC Neurosci. 2025 Jul 1;26(1):37. doi: 10.1186/s12868-025-00956-6. BMC Neurosci. 2025. PMID: 40597639 Free PMC article.
-
The Identification of a Key Regulator of Mitochondrial Metabolism, the LRPPRC Protein, as a Novel Therapeutic Target in SDHA-Overexpressing Ovarian Tumors.Cancers (Basel). 2025 Jun 11;17(12):1942. doi: 10.3390/cancers17121942. Cancers (Basel). 2025. PMID: 40563592 Free PMC article.
-
Review projecting shikonin as a therapeutic candidate in female carcinomas: a preclinical perspective.Front Pharmacol. 2025 Jul 4;16:1627124. doi: 10.3389/fphar.2025.1627124. eCollection 2025. Front Pharmacol. 2025. PMID: 40689201 Free PMC article. Review.
References
-
- Chen X. Y. (2009). Effect of Shikonin on Reversal of Drug Resistance and Expression of MRP and LRP in JAR/MTX Cells of Choriocarcinoma. Changchun: Jilin University. [D].
-
- Commission (2020). Pharmacopoeia of People’s Republic of China:One Edition. Beijing: China Medical Science Press, 355–356. [M].
-
- Du C. S., Wang S., Zhang F., Yu M. X., Song X. K., Wang C. (2018). Inhibitory Effect of Alkannin Combined with Cisplatin on Hela Cells of Cervical Carcinoma and its Mechanism. J. Shenyang Pharm. Univ. 35 (3), 232–237. [J]. 10.14066/j.cnki.cn21-1349/r.2018.03.012 - DOI
Publication types
LinkOut - more resources
Full Text Sources